{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-016797","form_type":"8-K/A","ticker":"TVGN","cik":"0001860871","company_name":"Tevogen Bio Holdings Inc.","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.947040+00:00","generated_at":"2026-06-03T05:46:06.843509+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tevogen Bio's audited FY2023 shows $60.5M net loss, going concern doubt","bullets":["Net loss of $60.5M in 2023 vs $22.0M in 2022; accumulated deficit $99.7M.","Cash of $1.05M as of Dec 31, 2023; management cites substantial doubt about going concern.","Convertible promissory notes total $94.9M, with $80.7M current; fair value change of $50.4M recorded as loss.","Total operating expenses $8.8M (R&D $4.4M, G&A $4.4M), down from $13.7M in 2022.","Business combination with Semper Paratus closed Feb 14, 2024; post-merger financing included $2M Series A and $1.2M Series A-1 preferred."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-016797","json":"https://secwatch.observer/filing/0001493152-24-016797.json","markdown":"https://secwatch.observer/filing/0001493152-24-016797.md","text":"https://secwatch.observer/filing/0001493152-24-016797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860871/000149315224016797/0001493152-24-016797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860871/000149315224016797/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:46:06.843509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}